Author Archives: admin


Stem Cell Clinic > Articles by: admin

RenovaCare Announces Organizational Changes and Appointment of New Officers – GlobeNewswire

By Stem Cell Medicine

ROSELAND, N.J., March 30, 2021 (GLOBE NEWSWIRE) -- RenovaCare, Inc. (Symbol: RCAR;www.renovacareinc.com), developer of patented technologies for spraying self-donated stem cells for the regeneration of organs and tissues, announced today that its Chairman, Chief Executive Officer, and President, Mr. Alan Rubino, has decided to retire. I am proud of all that has been accomplished at RenovaCare with our management team during my leadership tenure, stated Mr. Rubino. I wish the Company and its shareholders continued success as it prepares to commence its initial clinical studies.

Mr. Rubino formally resigned as the Companys Chairman, CEO, and President and from its Board of Directors on and effective as of March 25, 2021. To ensure an orderly management transition, Mr. Rubino will continue to provide consulting services to the Company, its senior management staff and the team of contract bioengineers, MD-PhDs, cell biologists, and support staff at Renovacares R&D Innovation Center in Berlin, Germany.

On March 26, 2021, the Companys Board of Directors appointed Dr. Kaiyo Nedd to serve as the Companys Interim President and Chief Executive Officer and Mr. Harmel S. Rayat, to serve as the Companys Chairman, effective March 26, 2021. Both Dr. Nedd and Mr. Rayat will serve as members of the Companys Board of Directors.

Dr. Nedd has been a practicing medical doctor for over 20 years in Vancouver, British Columbia. He was educated at the University of British Columbia and MD. Howard University and the College of Medicine Washington D.C. before undertaking emergency medicine rotation training at Harvard University Brigham and Womens Hospital and family practice residency training at St. Pauls Hospital in Vancouver, completing the same in 2002.

Since 2002, Dr. Nedd has acted as medical director of West End Medical Centre in Vancouver, which has provided Dr. Nedd broad patient exposure, involvement in several clinical trials and regular participation on pharmaceutical company advisory boards. In recent years, Dr. Nedds focus has been on chronic pain and mental health and has had deep clinical experience with the use of Cannabinoids and in the management of these conditions and continues to keep abreast of ongoing clinical research, as well as digital health care solutions and telemedicine.

Dr. Nedd has served on the board of Doctors of BC, which founded in 1900 and is an association of 14,000 physicians and medical students. During his tenure between 2013 and 2017, he created and oversaw the development of new health delivery systems and negotiated with government and private agencies for the financing of new initiatives.

Mr. Rayat, newly appointed as Chairman and member of the Board of Directors, has been a long-time majority stockholder and financial supporter of RenovaCare. Through his family office, Kalen Capital Corporation, he has invested over $20 million since 2013.

Mr. Rayats support has been key to advancing the SkinGun spray device and CellMist System from an unpatented technology to a technology platform with eight patent families, numerous peer reviewed articles and conditional FDA approval of its Investigational Device Exemption application to conduct a clinical trial to evaluate safety and feasibility. Mr. Rayat previously served the Company in a variety of capacities, including, at various times, as its President and Chief Executive Officer, Chairman and as a member of the Companys Board of Directors.

Beginning his career in the financial industry as a messenger and mail-room clerk in a stock brokerage firm in 1981, Mr. Rayat has since invested in a wide range of businesses and sectors, ranging from auto wreckers and alternative energy to raw land and artificial livers.

In recent years, and in addition to commercial real estate in Canada and the United States, Mr. Rayat has narrowed his focus to impact investing. His stated goal is to help inventors, entrepreneurs, and scientists to create and commercialize products and technologies that will have a beneficial impact on society at large.

About RenovaCare

RenovaCare, Inc. is developing new generation autologous stem cell therapies for the regeneration of human organs and tissues. The Companys initial product under development targets the bodys largest organ, the skin. The Companys flagship technology, the CellMist System, renders single-cell suspensions of tissue-specific pluripotent cells from donor tissues through sequential protease digestions. The RenovaCare CellMist System facilitates rapid healing of wounds or other afflicted tissues when applied topically as a gentle cell mist using the patented RenovaCare SkinGun. The Companys SkinGun is used to spray a liquid suspension of a patients stem cells the CellMist Solution on to wounds.

Development for next-generation biomedical technologies and devices for addressing unmet medical needs and commercialization is taking place at the RenovaCare R&D Innovation Center, located at StemCell Systems in Berlin, Germany. The Innovation Center houses dedicated RenovaCare cell biology laboratories; additional engineering, fabrication, prototyping and performance testing facilities; and product design studios for medical devices and biomedical products. Experienced contract bioengineers, cell biologists, and support staff work under the direction of a team of MD-PhDs who are experts in regenerative medicine, new product development, and clinical translation.

RenovaCare products are currently in development. They are not available for sale in the United States. There is no assurance that the Companys planned or filed submissions to the U.S. Food and Drug Administration will be accepted or cleared by the FDA.

For additional information, please call Amit Singh at: 1-888-398-0202 or visit:https://renovacareinc.com

To receive future press releases via email, please visit: https://renovacareinc.com/investors/register/ Follow us on LinkedIn:https://www.linkedin.com/company/renovacare-inc-/ Follow us on Twitter:https://twitter.com/RenovaCareInc Follow us on Facebook:https://www.facebook.com/renovacarercar

Social Media Disclaimer

Investors and others should note that we announce material financial information to our investors using SEC filings and press releases. We use our website and social media to communicate with our subscribers, shareholders and the public about the company, RenovaCare, Inc. development, and other corporate matters that are in the public domain. At this time, the company will not post information on social media that could be deemed to be material information unless that information was distributed to public distribution channels first. We encourage investors, the media, and others interested in the company to review the information we post on the companys website and the social media channels listed below:

* This list may be updated from time to time.

Legal Notice Regarding Forward-Looking Statements

No statement herein should be considered an offer or a solicitation of an offer for the purchase or sale of any securities. This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although RenovaCare, Inc. (the Company) believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words may, will, should, could, expect, anticipate, estimate, believe, intend, or project or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: the timing and success of clinical and preclinical studies of product candidates, the potential timing and success of the Companys product programs through their individual product development and regulatory approval processes, adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, termination of contracts or agreements, obsolescence of the Companys technologies, technical problems with the Companys research, price increases for supplies and components, litigation and administrative proceedings involving the Company, the possible acquisition of new businesses or technologies that result in operating losses or that do not perform as anticipated, unanticipated losses, the possible fluctuation and volatility of the Companys operating results, financial condition and stock price, losses incurred in litigating and settling cases, dilution in the Companys ownership of its business, adverse publicity and news coverage, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists, and other risks. There can be no assurance that further research and development will validate and support the results of our preliminary research and studies. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that the Company will be able to develop commercially viable products on the basis of its technologies. In addition, other factors that could cause actual results to differ materially are discussed in the Companys most recent Form 10-Q and Form 10-K filings with the Securities and Exchange Commission. These reports and filings may be inspected and copied at the Public Reference Room maintained by the U.S. Securities & Exchange Commission at 100 F Street, N.E., Washington, D.C. 20549. You can obtain information about operation of the Public Reference Room by calling the U.S. Securities & Exchange Commission at 1-800-SEC-0330. The U.S. Securities & Exchange Commission also maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the U.S. Securities & Exchange Commission athttp://www.sec.gov. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/8c5a17e6-34fc-42c3-b39a-c3194e4b9472

Go here to see the original:
RenovaCare Announces Organizational Changes and Appointment of New Officers - GlobeNewswire

Outlook on the Cell Therapy Global Market to 2027 – by Therapy Type, Product, Technology, Application, End-user and Geography – GlobeNewswire

By Somatic Stem Cells

Dublin, March 31, 2021 (GLOBE NEWSWIRE) -- The "Cell Therapy Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Therapy Type; Product; Technology; Application; End User, and Geography" report has been added to ResearchAndMarkets.com's offering.

According to this report the global cell therapy market is expected to reach US$ 12,563.23 million by 2027 from US$ 7,260.50 million in 2019. It is estimated to grow at a CAGR of 7.2% from 2020-2027. The growth of the market is attributed to increasing prevalence of chronic diseases, rising adoption of regenerative medicines, and surging number of approvals for cell-based therapies. However, the high cost of cell therapy manufacturing hinders the growth of the market.

The cell therapy market, based on therapy type, is bifurcated into allogeneic and autologous. In 2019, the allogeneic segment accounted for a larger share owing to the availability of substantial number of approved products for clinical use. For instance, in 2018, Alofisel developed by TiGenix (Takeda) is the first allogeneic stem cell-based therapy approved for use in Europe.

Chronic diseases, such as cardiovascular disorders, neurological disorders, autoimmune disorders, and cancer, are the leading causes of death and disability worldwide. As per the Centers for Disease Control and Prevention (CDC), in 2019, nearly 6 in 10 people suffered from at least one chronic disease in the US. Cardiovascular diseases (CVDs) are a significant cause of mortality owing to the hectic lifestyle. As per the World Health Organization (WHO), CVDs are the number 1 cause of death globally, taking an estimated 17.9 million lives each year. Cancer is among the leading causes of mortality worldwide, and the disease affects a huge population; therefore, it acts as a huge financial burden on society. According to the WHO, in 2018, ~9.6 million deaths occurred due to cancer globally. However, growing research on developing effective treatments for the disease is positively affecting the market growth. Gene therapy and cell therapy are transforming the cancer treatment landscape; for example, Novartis Kymriah is used to treat diffuse large B-cell lymphoma. The launches of more such products would be driving the demand for cell therapy, thus driving the growth of the cell therapy market in the coming years.

The COVID-19 outbreak was first reported in Wuhan (China) in December 2019. The pandemic is causing massive disruptions in supply chains, consumer markets, and economy across the world. As the healthcare sector is focusing on saving lives of COVID-19 patients, the demand for cell therapy is reducing worldwide.

Vericel Corporation; MEDIPOST; NuVasive, Inc.; Mesoblast Limited; JCR Pharmaceuticals Co. Ltd.; Smith & Nephew; Bristol-Myers Squibb Company; Cells for Cells; Stemedica Cell Technologies, Inc; and Castle Creek Biosciences, Inc. are among the companies operating in the cell therapy market.

Reasons to Buy

Key Topics Covered:

1. Introduction 1.1 Scope of the Study 1.2 Research Report Guidance 1.3 Market Segmentation 1.3.1 Global Cell Therapy Market - By Therapy Type 1.3.2 Global Cell Therapy Market - By Product 1.3.3 Global Cell Therapy Market - By Technology 1.3.4 Global Cell Therapy Market - By Application 1.3.5 Global Cell Therapy Market - By End User 1.3.6 Global Cell Therapy Market - By Geography

2. Cell Therapy Market - Key Takeaways

3. Research Methodology 3.1 Coverage 3.2 Secondary Research 3.3 Primary Research

4. Global Cell therapy- Market Landscape 4.1 Overview 4.2 PEST Analysis 4.2.1 North America - PEST Analysis 4.2.2 Europe- PEST Analysis 4.2.3 Asia Pacific- PEST Analysis 4.2.4 Middle East and Africa - PEST Analysis 4.2.5 South and Central America - PEST Analysis 4.3 Expert Opinions

5. Global Cell Therapy Market - Key Industry Dynamics 5.1 Key Market Drivers 5.1.1 Increasing Prevalence of Chronic Diseases 5.1.2 Rising Adoption of Regenerative Medicines 5.1.3 Increasing Number of Approvals for Cell-Based Therapies 5.2 Key Market Restraints 5.2.1 High Cost of Cell Therapy Manufacturing 5.3 Key Market Opportunities 5.3.1 Increasing Adoption of Cell Therapy in Developing Regions 5.4 Future Trends 5.4.1 Shift Toward Automated Cell Therapy Manufacturing 5.5 Impact Analysis of Drivers and Restraints

6. Cell therapy Market - Global Analysis 6.1 Global Cell therapy Market Revenue Forecast And Analysis 6.2 Global Cell therapy Market, By Geography - Forecast And Analysis 6.3 Market Positioning

7. Cell therapy Market Analysis - By Therapy Type 7.1 Overview 7.2 Cell therapy Market Revenue Share, by Therapy Type (2019 and 2027) 7.3 Allogeneic 7.3.1 Overview 7.3.2 Allogeneic: Cell therapy Market - Revenue and Forecast to 2027 (US$ Million) 7.4 Autologous 7.4.1 Overview 7.4.2 Autologous: Cell therapy Market - Revenue and Forecast to 2027 (US$ Million)

8. Cell therapy Market Analysis - By Product 8.1 Overview 8.2 Cell therapy Market Revenue Share, by Product (2019 and 2027) 8.3 Consumables 8.3.1 Overview 8.3.2 Consumables: Cell therapy Market - Revenue and Forecast to 2027 (US$ Million) 8.4 Equipment 8.4.1 Overview 8.4.2 Equipment: Cell therapy Market - Revenue and Forecast to 2027 (US$ Million) 8.5 Systems and Software 8.5.1 Overview 8.5.2 Systems and Software: Cell therapy Market - Revenue and Forecast to 2027 (US$ Million)

9. Cell therapy Market Analysis - By Technology 9.1 Overview 9.2 Cell therapy Market Revenue Share, by Technology (2019 and 2027) 9.3 Viral Vector Technology 9.3.1 Overview 9.3.2 Viral Vector Technology: Cell therapy Market - Revenue and Forecast to 2027 (US$ Million) 9.4 Genome Editing Technology 9.4.1 Overview 9.4.2 Genome Editing Technology: Cell therapy Market - Revenue and Forecast to 2027 (US$ Million) 9.5 Somatic Cell Technology 9.5.1 Overview 9.5.2 Somatic Cell Technology: Cell therapy Market - Revenue and Forecast to 2027 (US$ Million) 9.6 Cell Immortalization Technology 9.6.1 Overview 9.6.2 Cell Immortalization Technology: Cell therapy Market - Revenue and Forecast to 2027 (US$ Million) 9.7 Cell Plasticity Technology 9.7.1 Overview 9.7.2 Cell Plasticity Technology: Cell therapy Market - Revenue and Forecast to 2027 (US$ Million) 9.8 Three-Dimensional Technology 9.8.1 Overview 9.8.2 Three-Dimensional Technology: Cell therapy Market - Revenue and Forecast to 2027 (US$ Million)

10. Cell therapy Market Analysis - By Application 10.1 Overview 10.2 Cell therapy Market Revenue Share, by Application (2019 and 2027) 10.3 Oncology 10.3.1 Overview 10.3.2 Oncology: Cell therapy Market - Revenue and Forecast to 2027 (US$ Million) 10.4 Cardiovascular 10.4.1 Overview 10.4.2 Cardiovascular: Cell therapy Market - Revenue and Forecast to 2027 (US$ Million) 10.5 Orthopedic 10.5.1 Overview 10.5.2 Orthopedic: Cell therapy Market - Revenue and Forecast to 2027 (US$ Million) 10.6 Wound Management 10.6.1 Overview 10.6.2 Wound Management: Cell therapy Market - Revenue and Forecast to 2027 (US$ Million) 10.7 Other Applications 10.7.1 Overview 10.7.2 Other Applications: Cell therapy Market - Revenue and Forecast to 2027 (US$ Million)

11. Cell therapy Market Analysis - By End User 11.1 Overview 11.2 Cell therapy Market Share, by End User, 2019 and 2027, (%) 11.3 Hospitals 11.3.1 Overview 11.3.2 Hospitals: Cell therapy Market - Revenue and Forecast to 2027 (US$ Million) 11.4 Research Institutes 11.4.1 Overview 11.4.2 Research Institutes: Cell therapy Market - Revenue and Forecast to 2027 (US$ Million) 11.5 Others 11.5.1 Overview 11.5.2 Others: Cell therapy Market - Revenue and Forecast to 2027 (US$ Million)

12. Cell therapy Market - Geographic Analysis 12.1 North America: Cell Therapy Market 12.2 Europe: Cell therapy Market 12.3 Asia Pacific: Cell Therapy Market 12.4 Middle East and Africa: Cell Therapy Market 12.5 South and Central America: Cell Therapy Market

13. Impact of COVID-19 Pandemic on Global Cell Therapy Market 13.1 North America: Impact Assessment of COVID-19 Pandemic 13.2 Europe: Impact Assessment of COVID-19 Pandemic 13.3 Asia-Pacific: Impact Assessment of COVID-19 Pandemic 13.4 Middle East & Africa: Impact Assessment of COVID-19 Pandemic 13.5 South & Central America: Impact Assessment of COVID-19 Pandemic

14. Cell Therapy Market- Industry Landscape 14.1 Overview 14.2 Growth Strategies Done by the Companies in the Market, (%) 14.3 Organic Developments 14.3.1 Overview 14.4 Inorganic Developments 14.4.1 Overview

15. Company Profiles 15.1 Vericel Corporation 15.1.1 Key Facts 15.1.2 Business Description 15.1.3 Products and Services 15.1.4 Financial Overview 15.1.5 SWOT Analysis 15.1.6 Key Developments 15.2 MEDIPOST 15.2.1 Key Facts 15.2.2 Business Description 15.2.3 Products and Services 15.2.4 Financial Overview 15.2.5 SWOT Analysis 15.2.6 Key Developments 15.3 NuVasive, Inc. 15.3.1 Key Facts 15.3.2 Business Description 15.3.3 Products and Services 15.3.4 Financial Overview 15.3.5 SWOT Analysis 15.3.6 Key Developments 15.4 Mesoblast Limited 15.4.1 Key Facts 15.4.2 Business Description 15.4.3 Products and Services 15.4.4 Financial Overview 15.4.5 SWOT Analysis 15.4.6 Key Developments 15.5 JCR Pharmaceuticals Co. Ltd. 15.5.1 Key Facts 15.5.2 Business Description 15.5.3 Products and Services 15.5.4 Financial Overview 15.5.5 SWOT Analysis 15.5.6 Key Developments 15.6 Smith & Nephew 15.6.1 Key Facts 15.6.2 Business Description 15.6.3 Products and Services 15.6.4 Financial Overview 15.6.5 SWOT Analysis 15.6.6 Key Developments 15.7 Bristol-Myers Squibb Company 15.7.1 Key Facts 15.7.2 Business Description 15.7.3 Products and Services 15.7.4 Financial Overview 15.7.5 SWOT Analysis 15.7.6 Key Developments 15.8 Cells for Cells 15.8.1 Key Facts 15.8.2 Business Description 15.8.3 Products and Services 15.8.4 Financial Overview 15.8.5 SWOT Analysis 15.8.6 Key Developments 15.9 Stemedica Cell Technologies, Inc 15.9.1 Key Facts 15.9.2 Business Description 15.9.3 Products and Services 15.9.4 Financial Overview 15.9.5 SWOT Analysis 15.9.6 Key Developments 15.10 Castle Creek Biosciences, Inc. 15.10.1 Key Facts 15.10.2 Business Description 15.10.3 Products and Services 15.10.4 Financial Overview 15.10.5 SWOT Analysis 15.10.6 Key Developments

16. Appendix 16.1 About the Publisher 16.2 Glossary of Terms

For more information about this report visit https://www.researchandmarkets.com/r/yyd0c

Continue reading here:
Outlook on the Cell Therapy Global Market to 2027 - by Therapy Type, Product, Technology, Application, End-user and Geography - GlobeNewswire

Worldwide Cell Therapy Industry to 2027 – Increasing Prevalence of Chronic Diseases is Driving the Market – PRNewswire

By Somatic Stem Cells

DUBLIN, April 1, 2021 /PRNewswire/ -- The "Cell Therapy Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Therapy Type; Product; Technology; Application; End User, and Geography" report has been added to ResearchAndMarkets.com's offering.

According to this report the global cell therapy market is expected to reach US$ 12,563.23 million by 2027 from US$ 7,260.50 million in 2019. It is estimated to grow at a CAGR of 7.2% from 2020-2027. The growth of the market is attributed to increasing prevalence of chronic diseases, rising adoption of regenerative medicines, and surging number of approvals for cell-based therapies. However, the high cost of cell therapy manufacturing hinders the growth of the market.

The cell therapy market, based on therapy type, is bifurcated into allogeneic and autologous. In 2019, the allogeneic segment accounted for a larger share owing to the availability of substantial number of approved products for clinical use. For instance, in 2018, Alofisel developed by TiGenix (Takeda) is the first allogeneic stem cell-based therapy approved for use in Europe.

Chronic diseases, such as cardiovascular disorders, neurological disorders, autoimmune disorders, and cancer, are the leading causes of death and disability worldwide. As per the Centers for Disease Control and Prevention (CDC), in 2019, nearly 6 in 10 people suffered from at least one chronic disease in the US. Cardiovascular diseases (CVDs) are a significant cause of mortality owing to the hectic lifestyle. As per the World Health Organization (WHO), CVDs are the number 1 cause of death globally, taking an estimated 17.9 million lives each year. Cancer is among the leading causes of mortality worldwide, and the disease affects a huge population; therefore, it acts as a huge financial burden on society. According to the WHO, in 2018, ~9.6 million deaths occurred due to cancer globally. However, growing research on developing effective treatments for the disease is positively affecting the market growth. Gene therapy and cell therapy are transforming the cancer treatment landscape; for example, Novartis Kymriah is used to treat diffuse large B-cell lymphoma. The launches of more such products would be driving the demand for cell therapy, thus driving the growth of the cell therapy market in the coming years.

The COVID-19 outbreak was first reported in Wuhan (China) in December 2019. The pandemic is causing massive disruptions in supply chains, consumer markets, and economy across the world. As the healthcare sector is focusing on saving lives of COVID-19 patients, the demand for cell therapy is reducing worldwide.

Vericel Corporation; MEDIPOST; NuVasive, Inc.; Mesoblast Limited; JCR Pharmaceuticals Co. Ltd.; Smith & Nephew; Bristol-Myers Squibb Company; Cells for Cells; Stemedica Cell Technologies, Inc; and Castle Creek Biosciences, Inc. are among the companies operating in the cell therapy market.

Reasons to Buy

Key Topics Covered:

1. Introduction 1.1 Scope of the Study 1.2 Research Report Guidance 1.3 Market Segmentation 1.3.1 Global Cell Therapy Market - By Therapy Type 1.3.2 Global Cell Therapy Market - By Product 1.3.3 Global Cell Therapy Market - By Technology 1.3.4 Global Cell Therapy Market - By Application 1.3.5 Global Cell Therapy Market - By End User 1.3.6 Global Cell Therapy Market - By Geography

2. Cell Therapy Market - Key Takeaways

3. Research Methodology 3.1 Coverage 3.2 Secondary Research 3.3 Primary Research

4. Global Cell therapy- Market Landscape 4.1 Overview 4.2 PEST Analysis 4.2.1 North America - PEST Analysis 4.2.2 Europe- PEST Analysis 4.2.3 Asia Pacific- PEST Analysis 4.2.4 Middle East and Africa - PEST Analysis 4.2.5 South and Central America - PEST Analysis 4.3 Expert Opinions

5. Global Cell Therapy Market - Key Industry Dynamics 5.1 Key Market Drivers 5.1.1 Increasing Prevalence of Chronic Diseases 5.1.2 Rising Adoption of Regenerative Medicines 5.1.3 Increasing Number of Approvals for Cell-Based Therapies 5.2 Key Market Restraints 5.2.1 High Cost of Cell Therapy Manufacturing 5.3 Key Market Opportunities 5.3.1 Increasing Adoption of Cell Therapy in Developing Regions 5.4 Future Trends 5.4.1 Shift Toward Automated Cell Therapy Manufacturing 5.5 Impact Analysis of Drivers and Restraints

6. Cell therapy Market - Global Analysis 6.1 Global Cell therapy Market Revenue Forecast And Analysis 6.2 Global Cell therapy Market, By Geography - Forecast And Analysis 6.3 Market Positioning

7. Cell therapy Market Analysis - By Therapy Type 7.1 Overview 7.2 Cell therapy Market Revenue Share, by Therapy Type (2019 and 2027) 7.3 Allogeneic 7.3.1 Overview 7.3.2 Allogeneic: Cell therapy Market - Revenue and Forecast to 2027 (US$ Million) 7.4 Autologous 7.4.1 Overview 7.4.2 Autologous: Cell therapy Market - Revenue and Forecast to 2027 (US$ Million)

8. Cell therapy Market Analysis - By Product 8.1 Overview 8.2 Cell therapy Market Revenue Share, by Product (2019 and 2027) 8.3 Consumables 8.3.1 Overview 8.3.2 Consumables: Cell therapy Market - Revenue and Forecast to 2027 (US$ Million) 8.4 Equipment 8.4.1 Overview 8.4.2 Equipment: Cell therapy Market - Revenue and Forecast to 2027 (US$ Million) 8.5 Systems and Software 8.5.1 Overview 8.5.2 Systems and Software: Cell therapy Market - Revenue and Forecast to 2027 (US$ Million)

9. Cell therapy Market Analysis - By Technology 9.1 Overview 9.2 Cell therapy Market Revenue Share, by Technology (2019 and 2027) 9.3 Viral Vector Technology 9.3.1 Overview 9.3.2 Viral Vector Technology: Cell therapy Market - Revenue and Forecast to 2027 (US$ Million) 9.4 Genome Editing Technology 9.4.1 Overview 9.4.2 Genome Editing Technology: Cell therapy Market - Revenue and Forecast to 2027 (US$ Million) 9.5 Somatic Cell Technology 9.5.1 Overview 9.5.2 Somatic Cell Technology: Cell therapy Market - Revenue and Forecast to 2027 (US$ Million) 9.6 Cell Immortalization Technology 9.6.1 Overview 9.6.2 Cell Immortalization Technology: Cell therapy Market - Revenue and Forecast to 2027 (US$ Million) 9.7 Cell Plasticity Technology 9.7.1 Overview 9.7.2 Cell Plasticity Technology: Cell therapy Market - Revenue and Forecast to 2027 (US$ Million) 9.8 Three-Dimensional Technology 9.8.1 Overview 9.8.2 Three-Dimensional Technology: Cell therapy Market - Revenue and Forecast to 2027 (US$ Million)

10. Cell therapy Market Analysis - By Application 10.1 Overview 10.2 Cell therapy Market Revenue Share, by Application (2019 and 2027) 10.3 Oncology 10.3.1 Overview 10.3.2 Oncology: Cell therapy Market - Revenue and Forecast to 2027 (US$ Million) 10.4 Cardiovascular 10.4.1 Overview 10.4.2 Cardiovascular: Cell therapy Market - Revenue and Forecast to 2027 (US$ Million) 10.5 Orthopedic 10.5.1 Overview 10.5.2 Orthopedic: Cell therapy Market - Revenue and Forecast to 2027 (US$ Million) 10.6 Wound Management 10.6.1 Overview 10.6.2 Wound Management: Cell therapy Market - Revenue and Forecast to 2027 (US$ Million) 10.7 Other Applications 10.7.1 Overview 10.7.2 Other Applications: Cell therapy Market - Revenue and Forecast to 2027 (US$ Million)

11. Cell therapy Market Analysis - By End User 11.1 Overview 11.2 Cell therapy Market Share, by End User, 2019 and 2027, (%) 11.3 Hospitals 11.3.1 Overview 11.3.2 Hospitals: Cell therapy Market - Revenue and Forecast to 2027 (US$ Million) 11.4 Research Institutes 11.4.1 Overview 11.4.2 Research Institutes: Cell therapy Market - Revenue and Forecast to 2027 (US$ Million) 11.5 Others 11.5.1 Overview 11.5.2 Others: Cell therapy Market - Revenue and Forecast to 2027 (US$ Million)

12. Cell therapy Market - Geographic Analysis 12.1 North America: Cell Therapy Market 12.2 Europe: Cell therapy Market 12.3 Asia Pacific: Cell Therapy Market 12.4 Middle East and Africa: Cell Therapy Market 12.5 South and Central America: Cell Therapy Market

13. Impact of COVID-19 Pandemic on Global Cell Therapy Market 13.1 North America: Impact Assessment of COVID-19 Pandemic 13.2 Europe: Impact Assessment of COVID-19 Pandemic 13.3 Asia-Pacific: Impact Assessment of COVID-19 Pandemic 13.4 Middle East & Africa: Impact Assessment of COVID-19 Pandemic 13.5 South & Central America: Impact Assessment of COVID-19 Pandemic

14. Cell Therapy Market- Industry Landscape 14.1 Overview 14.2 Growth Strategies Done by the Companies in the Market, (%) 14.3 Organic Developments 14.3.1 Overview 14.4 Inorganic Developments 14.4.1 Overview

15. Company Profiles 15.1 Vericel Corporation 15.1.1 Key Facts 15.1.2 Business Description 15.1.3 Products and Services 15.1.4 Financial Overview 15.1.5 SWOT Analysis 15.1.6 Key Developments 15.2 MEDIPOST 15.2.1 Key Facts 15.2.2 Business Description 15.2.3 Products and Services 15.2.4 Financial Overview 15.2.5 SWOT Analysis 15.2.6 Key Developments 15.3 NuVasive, Inc. 15.3.1 Key Facts 15.3.2 Business Description 15.3.3 Products and Services 15.3.4 Financial Overview 15.3.5 SWOT Analysis 15.3.6 Key Developments 15.4 Mesoblast Limited 15.4.1 Key Facts 15.4.2 Business Description 15.4.3 Products and Services 15.4.4 Financial Overview 15.4.5 SWOT Analysis 15.4.6 Key Developments 15.5 JCR Pharmaceuticals Co. Ltd. 15.5.1 Key Facts 15.5.2 Business Description 15.5.3 Products and Services 15.5.4 Financial Overview 15.5.5 SWOT Analysis 15.5.6 Key Developments 15.6 Smith & Nephew 15.6.1 Key Facts 15.6.2 Business Description 15.6.3 Products and Services 15.6.4 Financial Overview 15.6.5 SWOT Analysis 15.6.6 Key Developments 15.7 Bristol-Myers Squibb Company 15.7.1 Key Facts 15.7.2 Business Description 15.7.3 Products and Services 15.7.4 Financial Overview 15.7.5 SWOT Analysis 15.7.6 Key Developments 15.8 Cells for Cells 15.8.1 Key Facts 15.8.2 Business Description 15.8.3 Products and Services 15.8.4 Financial Overview 15.8.5 SWOT Analysis 15.8.6 Key Developments 15.9 Stemedica Cell Technologies, Inc 15.9.1 Key Facts 15.9.2 Business Description 15.9.3 Products and Services 15.9.4 Financial Overview 15.9.5 SWOT Analysis 15.9.6 Key Developments 15.10 Castle Creek Biosciences, Inc. 15.10.1 Key Facts 15.10.2 Business Description 15.10.3 Products and Services 15.10.4 Financial Overview 15.10.5 SWOT Analysis 15.10.6 Key Developments

16. Appendix 16.1 About the Publisher 16.2 Glossary of Terms

For more information about this report visit https://www.researchandmarkets.com/r/hxk6k0

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Excerpt from:
Worldwide Cell Therapy Industry to 2027 - Increasing Prevalence of Chronic Diseases is Driving the Market - PRNewswire

Exclusive Report on Global Gene Therapy Market Analysis Report 2021 and Forecast to 2029 with different segments, Key players KSU | The Sentinel…

By Somatic Stem Cells

Global gene therapy market was valued at US$ 919.6 million in 2018 and is expected to reach US$ 5,609.9 million by 2027, growing at an estimated CAGR of 8.2% over the forecast period. The introduction of gene with the potential to cure or prevent the growth of a disease is termed as Gene Therapy. Increasing investment in research and development to discover lifesaving treatment for advanced diseases such as Cancer is driving the overall gene therapy market.

Gene therapy market is growing at a notable pace. Genetic or hereditary defects such as cardiovascular diseases, neurological disorders amongst others can be cured using gene therapy by introducing functional gene in the body and eliminating the defective ones. Gene therapy is categorized into somatic cell gene therapy and reproductive or germ line gene therapy. Gene therapy of Somatic cell are related to cells other than the germ cells or the reproductive cells while the germ line therapy are related to the reproductive cells with an objective to make changes to the hereditary factors to get the desired offspring. Somatic gene therapy can be further bifurcated into ex vivo gene therapy and in vivo gene therapy. In ex vivo gene therapy the cells are altered outside the body and the planted into the body while in the in vivo therapy cells are dealt inside the body. Somatic cell gene therapy is currently focusing on the treatment of tissue restricted disease such as Cystic Fibrosis, Adenosine Deaminase.

Get Sample Copy of this Report @

https://www.absolutemarketsinsights.com/request_sample.php?id=308

This market research report on the Global Gene Therapy Market is an all-inclusive study of the business sectors up-to-date outlines, industry enhancement drivers, and manacles. It provides market projections for the coming years. It contains an analysis of late augmentations in innovation, Porters five force model analysis and progressive profiles of hand-picked industry competitors. The report additionally formulates a survey of minor and full-scale factors charging for the new applicants in the market and the ones as of now in the market along with a systematic value chain exploration.

Top Key Players:

Some of the players operating in the gene therapy market are Voyager Therapeutics, Inc., Spark Therapeutics, Inc., Sangamo Therapeutics, Human Stem Cells Institute PJSC, Orchard Therapeutics plc, Genenta Science, Chiesi Farmaceutici S.p.A., Novartis AG, GlaxoSmithKline PLC, Gilead Sciences, Inc., Bristol Myers Squibb Delta Company Limited, Advanced Cell & Gene Therapy, LLC, Audentes Therapeutics, Inc., Biogen, and Pfizer Inc. amongst others.

Enquiry before Buying:

https://www.absolutemarketsinsights.com/enquiry_before_buying.php?id=308

The report answers important questions that companies may have when operating in the global Global Gene Therapy market. Some of the questions are given below:

What will be the size of the global Global Gene Therapy market in 2027? What is the current CAGR of the global Global Gene Therapy market? What products have the highest growth rates? Which application is projected to gain a lions share of the global Global Gene Therapy market? Which region is foretold to create the most number of opportunities in the global Global Gene Therapy market? Which are the top players currently operating in the global Global Gene Therapy market? How will the market situation change over the next few years? What are the common business tactics adopted by players? What is the growth outlook of the global Global Gene Therapy market?

Request For [emailprotected] https://www.absolutemarketsinsights.com/request_for_customization.php?id=308

About Us:

Absolute Markets Insights assists in providing accurate and latest trends related to consumer demand, consumer behavior, sales, and growth opportunities, for the better understanding of the market, thus helping in product designing, featuring, and demanding forecasts. Our experts provide you the end-products that can provide transparency, actionable data, cross-channel deployment program, performance, accurate testing capabilities and the ability to promote ongoing optimization.

From the in-depth analysis and segregation, we serve our clients to fulfill their immediate as well as ongoing research requirements. Minute analysis impact large decisions and thereby the source of business intelligence (BI) plays an important role, which keeps us upgraded with current and upcoming market scenarios.

Contact Us:

Company: Absolute Markets Insights

Email id: [emailprotected]

Phone: +91-740-024-2424

Contact Name: Shreyas Tanna

The Work Lab,

Model Colony, Shivajinagar, Pune, MH, 411016

Website: https://www.absolutemarketsinsights.com/

Link:
Exclusive Report on Global Gene Therapy Market Analysis Report 2021 and Forecast to 2029 with different segments, Key players KSU | The Sentinel...

BioRestorative Therapies Announces Notice of Allowance for a New Patent Application Related to its Off-the-Shelf ThermoStem Program -…

By Adult Stem Cells

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

MELVILLE, N.Y., March 31, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the Company) (OTC: BRTX), a life sciences company focused on stem cell-based therapies, today announced that the United States Patent Office has issued a notice of allowance for a patent application related to the Companys metabolic ThermoStem Program. The notice of allowance was issued on March 22, 2021 and is related to a new patent application not previously announced.

Claims granted under the new patent cover methodologies related to generating exosomes and brown adipocytes from human brown adipose-derived stem cells. Exosomes are small extracellular vesicles produced by cells that contain lipids, messenger-RNA, micro-RNA, cytokines and proteins. Therapeutic benefits of using exosomes have been demonstrated in various disease models and may provide a valuable therapeutic tool for treating disease.

We are pleased to see that we have been granted an additional patent by the USPTO for our ThermoStem Program, said Lance Alstodt, the Companys CEO. Our comprehensive portfolio of patents under our ThermoStem Program continues to expand as we develop and protect intellectual property related to large and growing markets where brown adipocyte therapeutics can be applied. Im very proud of our team, driving towards the achievement of our stated goals. The advancement of our technology is a core, fundamental value driver of our Company. Our family of intellectual property coupled with our financial reporting progress are critical factors contributing to our growth strategy.

It is expected that the exosome diagnostic and therapeutic market will reach $368 million by 2022 as the development of research, clinical tools and therapeutics continues to grow in this emerging technology.

About BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders:

Disc/Spine Program (brtxDISC): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a persons own) cultured mesenchymal stem cells collected from the patients bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complementary therapeutic to a surgical procedure. The BRTX-100 production process utilizes proprietary technology and involves collecting a patients bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patients damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. We have received authorization from the Food and Drug Administration to commence a Phase 2 clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease.

Metabolic Program (ThermoStem): We are developing a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in animals may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including, without limitation, those set forth in the Company's latest Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.

CONTACT:Email: ir@biorestorative.com

More:
BioRestorative Therapies Announces Notice of Allowance for a New Patent Application Related to its Off-the-Shelf ThermoStem Program -...

Transplant After CD19 CAR T-Cell Therapy Shows Durable Disease Control in Children, Young Adults With B-ALL – Cancer Network

By Adult Stem Cells

In a long-term follow-up of an early-phase trial examining CD19.28 chimeric antigen receptor (CAR) T-cell therapy, the use of consolidative allogeneic hematopoietic stem cell transplant (alloHSCT) was associated with long-term and durable disease control in children and young adults with B-cell acute lymphoblastic leukemia (B-ALL).

These results were based on a cohort of 20 patients who were initially treated in a dose-escalation part of a phase 1 trial (NCT01593696) examining anti-CD19 CAR T-cell therapy in patients between 1 and 30 years who have not responded to standard treatment, plus an additional 30 patients who were treated in an expansion portion. The median follow-up for all patients examined was 4.8 years and represents the longest time period examined for the use of this therapy in children and young adults with B-ALL.

We demonstrate that CD19.28 CAR T cells followed by a consolidative alloHSCT can provide long-term durable disease control in [child and young adult patients] with relapsed or refractory B-ALL, wrote the study investigators who were led by Nirali N. Shah, MD. Following alloHSCT, we observed a significant long-term [event-free survival (EFS)] with an apparent plateau and a low relapse rate, providing support for this sequential approach for long-term cure.

The complete response rate (CR) was 62.0%, with 28 of the 31 patients achieving this end point also reaching minimal residual disease (MRD) negativity by flow cytometry. The rate of CR was higher in patients with primary refractory disease (P = .0035), fewer prior lines of therapy (P = .033), and an M1 marrow (P = .0007). Additionally, CR rates were better for patients who received fludarabine/cyclophosphamidebased lymphodepletion versus other regimens, at 69% and 25%, respectively (P = .041).

The median overall survival (OS) for the cohort was 10.5 months (95% CI, 6.3-29.2 months). The median EFS was 3.1 months (95% CI, 0.9-7.7), with rates at 3 and 6 months of 52.0% (95% CI, 37.4%-64.7%) and 38.0% (95% CI, 24.8%-51.1%), respectively. Notably, median EFS was not reached in patients treated with M1 marrow versus 0.9 months in those with M2 marrow (P .0001).

Of the patients achieving MRD-negative CR (n = 28), 21 (75.0%) went on to receive consolidative alloHSCT, with a median time to transplant of 54 days from infusion (range, 42-97). The median OS from transplant day 0 was 70.2 months (95% CI, 10.4 months-not estimable) and the median EFS was not reached. The rate of EFS at 5 years was 61.9% (95% CI, 38.1%-78.8%). There were 8 deaths between 0.8 and 71 months following alloHSCT, which included transplant-related complications and/or graft-versus-host disease or infection in 6 patients and 1 patient with a complication of secondary malignancy at 3 years post-transplant. Teo patients relapsed after alloHSCT, with a cumulative risk of relapse was 4.8% (95% CI, 0.3-20.3) and 9.5% (95% CI, 1.5%-26.8%) at 12 and 24 months, respectively, with death as a competing risk.

Of note, achieving a CR was associated with greater CAR T-cell expansion and grade 3/4 cytokine release syndrome (CRS). Overall, CRS occurred in 70.0% of patients, with 9 (18.0%) having a grade 3/4 event. Neurotoxicity occurred in 10 patients (20.0%), with 4 having severe neurotoxicity.

Central nervous system involvement was effectively treated with CAR T-cell therapy all patients with a marrow response and CRS, although 1 patients did have residual disease by flow cytometry at low levels.

The authors noted that given these findings, CD19-directed CAR T-cell therapy may be considered as a bridge to alloHSCT versus standard-of-care blinatumomab (Blincyto).

Despite its more ready availability, which is not dependent on manufacturing time or success thereof, the efficacy of blinatumomab in children is lower than in adults receiving blinatumomab and also lower than remission rates following CD19-CAR T cells, using any construct, particularly for those with high-burden disease, the study author wrote. Therefore, selection of CAR T cells over blinatumomab may be advantageous in patients with higher-burden disease and [extramedullary] disease or as a salvage for blinatumomab nonresponders.

References

Shah NN, Lee DW, Yates B, et al. Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL. J Clin Oncol. March 25, 2021. doi: 10.1200/JCO.20.02262

Read more:
Transplant After CD19 CAR T-Cell Therapy Shows Durable Disease Control in Children, Young Adults With B-ALL - Cancer Network

Stem Cell Assay Market Changing Dynamics Of Competition With Forecast To 2030 The Bisouv Network – The Bisouv Network

By Adult Stem Cells

Market Industry Reports (MIR) has published a new report titled Stem Cell Assay Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 20192030. According to the report the global stem cell assay market was valued at over US$ 450.0 Mn. in 2017 and is anticipated to grow at a CAGR of 19.9% from 2019 to 2030.

The updated study released on Stem Cell Assay Market by Market Industry Reports is an ideal representation of all the ongoing happenings and activities in the market to help the manufacturers and the market player in planning crucial profitable strategies for the forecast period 2020 2030. The statistical research report presents recent industry insights, product analysis, historical data, and current information for offering a better market picture to the market players. Industry players can hence plan effective strategies for future and lead the market substantially. With higher profitability, market players can penetrate deeply in the Stem Cell Assay Market and ultimately emerge by implementing right strategies.

Get sample copy of Stem Cell Assay Market at: https://www.marketindustryreports.com/pdf/8

Some of the prominent players in the Stem Cell Assay Market include:

Thermo Fisher Scientific, Promega Corporation, STEMCELL Technologies Inc., Merck KGaA, GE Healthcare, Bio-Techne Corporation, Hemogenix, Bio-Rad Laboratories, Inc., Cellular Dynamics International Inc., and Cell Biolabs Inc.

Increasing global burden of diseases such as diabetes, cancer, and others are projected to be the major factors leading to the market growth. According to the World Health Organization (WHO) in 2017, number of patients suffering from type I and type II diabetes was estimated to be over 422 million. Moreover, the disease is expected to be the seventh largest cause of death by 2030.

According to American Cancer Society, in 2017, there were over 1.6 million new cancer cases in the U.S. Hence, there exists a need for developing new treatment methods which have led to the rise in approvals of clinical trials for the stem cell based therapies.

The Stem Cell Assay Market is segmented on the basis of Product, Modality, Cancer Type, End-Users and region.

by Product & Service (Instruments, Kits) Cell Type(Adult Stem Cells, Human Embryonic Stem Cells), Application (Regenerative Medicine, Drug Discovery, Clinical Research), Type (Cell Identification, Viability, Proliferation Assay)

Have any query? Inquiry about report: https://www.marketindustryreports.com/inquiry/8

The Research Report aims to resolve the following questions related to the Stem Cell Assay Market

Table of Contents

Buy this report @ https://www.marketindustryreports.com/checkout/8

About Market Industry Reports

Market Industry Reports is a global leader in market measurement & advisory services, Market Industry Reports is at the forefront of innovation to address the worldwide industry trends and opportunities. We identified the caliber of market dynamics & hence we excel in the areas of innovation and optimization, integrity, curiosity, customer and brand experience, and strategic business intelligence through our research.

We continue to pioneer state-of-the-art approach in research & analysis that makes complex world simpler to stay ahead of the curve. By nurturing the perception of genius and optimized market intelligence we bring proficient contingency to our clients in the evolving world of technologies, megatrends and industry convergence. We empower and inspire Vanguards to fuel and shape their business to build and grow world-class consumer products.

Contact Us-Email:[emailprotected] Phone:+ 91 8956767535 Website:https://www.marketindustryreports.com

See the original post here:
Stem Cell Assay Market Changing Dynamics Of Competition With Forecast To 2030 The Bisouv Network - The Bisouv Network

Gene Therapy for CNS Disorders Market 2021 Industry Size, Share, Growth and Top Companies Analysis- Gilead (Kite Pharma), Amgen (BioVex), Novartis,…

By Gene Therapy Clinics

DataIntelo recently publishes an all-inclusive report on the Global Gene Therapy for CNS Disorders Market providing a complete overview of the key aspects of the market. Gene Therapy for CNS Disorders market report makes a robust assessment regarding the current market situation and its scope, which are anticipated to impact significantly on the performance of the market during the forecast period, 2020-2027. This report includes an in-depth analysis about the COVID-19 situation and its possible impact on the market in the next few years. The report contains XX pages, which provides a precise and detailed explanation of key components and their market expansion scope in the mentioned period. The key insights about the potential size, volume, and dynamics of the market as mentioned in the report is a vital guideline that would help clients to make informed decision about their business investment plans and strategies in the market.

As per the analysis, the global Gene Therapy for CNS Disorders market was valued at USD XX million in 2019 and is projected to reach a value of USD XX million by the end of 2027, expanding at a CAGR of XX% during the forecast period.

Few of the key players mentioned in this report:

Gilead (Kite Pharma) Amgen (BioVex) Novartis Roche (Spark Therapeutics) Bluebird Bio

Get FREE Exclusive PDF Sample Copy of This Report: https://dataintelo.com/request-sample/?reportId=113131

The report covers a detailed study on key areas such as market size, scope, and growth opportunities of the global Gene Therapy for CNS Disorders market by analyzing the market trend and data available for the period prior to 2019. From this analysis, the report draws several observations and deduces about the key factors that drive or restrain the market growth, which would have a wide impact on the development and expansion of the market during the forecast period. Moreover, it covers a range of opportunities and challenges prevailing in the market that will help clients to evaluate their investment strategies.

The global Gene Therapy for CNS Disorders market report examine the major segments and sub-segmentations of the market that are classified as the product types, applications, and regions. In additional to the harsh economic impact of the COVID-19 outbreak, the report studies the dynamics of the market by analysis the key performance of each segments and the potential expansion scope of the segments in the coming years. Furthermore, the scope of the growth potential, revenue growth, product range, and pricing factors related to the global Gene Therapy for CNS Disorders market in terms of applications are thoroughly assessed in the report in a view to entail a broader picture of the market.

The report, published by DataIntelo, is the most reliable information as the study consists of a concise graphical representations, tables, and figures which allow the users to easily understand the key market position of sectors or segment without going through a deep study of the report. The tables and figures represent the latest update information that provides a broad picture of several market developments of the products and services over the last few years.

Customize Report and Inquiry for the Gene Therapy for CNS Disorders market report @ https://dataintelo.com/enquiry-before-buying/?reportId=113131

The market report relies on a concrete research methodology focusing on both primary as well as secondary sources. The report is prepared by relying on primary source including interviews of the company executives & representatives and accessing official documents, websites, and press release of the private and public companies. Additionally, this report includes market analysis from several global experts and analysts who have in-depth knowledge about the market. To ensure a complete framework of the market, it also adopts several research tools such as statistical surveying for SWOT analysis, PESTLE analysis, predictive analysis, and real-time analytics.

Global Gene Therapy for CNS Disorders market by Products

Ex Vivo In Vivo

Global Gene Therapy for CNS Disorders market by Applications

Hospitals Clinics Others

You can buy the complete report in PDF format @ https://dataintelo.com/checkout/?reportId=113131

The report mentions some key global players in the market and additional names of the players in the market can be included as per the clients request. Moreover, a customized or separate report can also be available according to the needs of clients. The report covers the recent development of players including merger & acquisition agreements, partnership or joint venture and latest products launches from the key manufacturers in the Gene Therapy for CNS Disorders market. Please contact with our sales team, who will deliver reports that suits your necessities.

Competition Landscape

The report covers global aspect of the market, covering

North America Latin America Europe Asia Pacific Middle East and Africa

About DataIntelo:

DataIntelo is a globally leading distributor of market research report that has experienced by dealing with more than 800+ global clients. We offer quality market research report and provide data that can help generate a totally new approach for our clients to help change the outlook of their investment and business. Our mission is singular and well-defined we want to help our clients envisage their business environment so that they are able to make informed, strategic and therefore successful decisions for themselves.

Contact Info:

Name: Alex Mathews

Address: 500 East E Street, Ontario,

CA 91764, United States.

Phone No: USA: +1 909 545 6473

Email:[emailprotected]

Website:https://dataintelo.com

See the original post:
Gene Therapy for CNS Disorders Market 2021 Industry Size, Share, Growth and Top Companies Analysis- Gilead (Kite Pharma), Amgen (BioVex), Novartis,...

Top Executives from AveXis Join New Gene Therapy Venture — This Time Targeting Tens of Millions More Patients – PRNewswire

By Gene Therapy Clinics

MADISON, Wis., March 29, 2021 /PRNewswire/ --A pair of top C-level Executives from blockbuster gene therapy company AveXis have joined ENDSULIN, a new venture that could reach millions more than any gene therapy to date. Spearheaded by one of the disease's most accomplished pioneers, the company aims to upend a multi-billion dollar treatment industry.

Both Brian Kaspar and Thomas Dee, the founding Chief Science and Chief Finance Officers, respectively, of AveXis (developer of Zolgensma, bought by Novartis for $8.7 Billionin May of 2018) have accepted board roles at ENDSULIN. While AveXis sought to "transform rare diseases," ENDSULIN is solely targeting one of the most prolific Type 1 diabetes (T1D) with what they hope will be a one-time treatment to free patients from daily insulin injections by more precisely regulating their glycemic control.

"The science itself is remarkable, but the potential to change millions of lives is unprecedented," Kaspar said. "We've proven gene therapy can revolutionize medicine with lasting, durable treatments. But now we need players like ENDSULIN with the right vision and focus who can harness that momentum to give patients the relief they deserve."

The former AveXis leaders round out a team of pioneering experts at the forefront of diabetes, gene therapy and drug development, strategically brought together to accelerate ENDSULIN's undivided focus: FDA authorization to begin human clinical trials.

Founder Hans Sollinger's previous discoveries have shaped modern pancreatic transplantation treatment for T1D. But because of the complexity of the disease, while the science of management has advanced, insulin shots have been the enduring standard of care since the 1920s almost a full century.

"25 years ago, I had performed more kidney-pancreas transplants than anyone in the world, but I'd only helped 500 people," Sollinger said. "The most important aspect of my search for a cure became its reach, in terms of both scale and accessibility. As I advanced, it became more and more obvious that gene therapy was the way to achieve it all, with no compromises."

Through decades of research at the UW Hospitals and Clinics, Sollinger's team developed a highly unique and targeted expression system that addresses one of the greatest challenges in treating T1D: precise regulation of insulin in response to rapidly fluctuating glucose levels. Several publications over the last 10 years have demonstratedlong-lasting euglycemia control in hundreds of mice and rats, indicating a durable cure may be within reach.

"We've focused everything we are doing around our mission to get this treatment to patients," said Eric Spyra, Interim CEO and Board Member. "Using existing commercial infrastructure and following the path of other liver-directed AAV gene therapies, we're putting all the pieces in place now that will accelerate this therapy through every stage."

ENDSULIN has already initiated a pilot study in autoimmune-modeled naturally diabetic companion dogs, while executing their IND-enabling plan and preclinical studies. The company is preparing for a Series A funding round this year.

ABOUT ENDSULIN ENDSULIN is reshaping the way we approach a cure for diabetes. They are working to free patients from daily injections and 24/7 management using the most cutting-edge gene therapy technology, developed from decades of research by noted diabetes leader Hans Sollinger, MD, PhD, Dr hc, at the University of Wisconsin Hospitals and Clinics. Their sole focus is to get a durable, one-time treatment to the millions of people who need it.

SOURCE ENDSULIN

http://www.endsulin.com

See more here:
Top Executives from AveXis Join New Gene Therapy Venture -- This Time Targeting Tens of Millions More Patients - PRNewswire

Gene Therapy for Hemophilia Market will Reach Thriving Value by 2019 to 2028 SoccerNurds – SoccerNurds

By Gene Therapy Clinics

A new research study titled Global Gene Therapy for Hemophilia market successfully portrays the entire global scenario as well as a detailed analysis of various regional segments.

Request Sample [emailprotected]https://insights10.com/free-sample-report-inquiry/?id=9158

The Gene Therapy for Hemophilia market research includes an examination of the leading geographies, such as North America (U.S., Canada), Europe (Germany, France, U.K., Spain, Italy, and Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Australia, and Rest of Asia Pacific) Latin America ( Mexico, Brazil, Rest of Latin America) and Middle East & Africa (GCC countries, South Africa, and Rest of Middle East & Africa) for the period of 2019 to 2028.

The study on the Gene Therapy for Hemophilia market is a detailed review and presentation of the global industrys drivers, constraints, opportunities, demand factors, market size, historical data forecasts, and trends from 2019 to 2028. The study also assists in the comprehension of global Gene Therapy for Hemophilia market dynamics and structure by defining and evaluating market segments, as well as forecasting global market size.

Top Participants in the Gene Therapy for Hemophilia Market

F. Hoffmann-La Roche AG, Pfizer Inc., BioMarin Pharmaceuticals, uniQure and, Shire PLC.

Global Gene Therapy for Hemophilia Market Segmentation

A. By Class

I. Viral Vector II. Non-Viral Vector

B. Distribution Channel

I. Hospital Pharmacies II. Clinics III. Others

C. Geography

I. North America Market Analysis II. Europe Market Analysis III. Asia-Pacific Market Analysis IV. Middle-East and Africa Market Analysis

View Detail [emailprotected]https://insights10.com/product/global-gene-therapy-hemophilia-market/

Table Of Content of Global Gene Therapy for Hemophilia Market

1. Global Gene Therapy for Hemophilia Market Overview. A. Market Size 2. Market Growth Drivers.. A. Rise in Global Prevalence of Gene Therapy for Hemophilia B. Growing R&D Investments and Reimbursement Policies 3. Gene Therapy for Hemophilia Market Segmentation. A. By Class I. Viral Vector II. Non-Viral Vector B. Distribution Channel I. Hospital Pharmacies II. Clinics III. Others C. Geography I. North America Market Analysis II. Europe Market Analysis III. Asia-Pacific Market Analysis IV. Middle-East and Africa Market Analysis 4. Gene Therapy for Hemophilia Disease Major Market Share.. A. Market Analysis, Insights and Forecast By Revenue 5. Competitive Landscape. A. Major Players B. Products in Pipeline 6. Key Company Profiles A. Pfizer overview, Product & Services, Strategies & Financials B. Shire PLC Company overview, Product & Services, Strategies & Financials C. Roche Company, Product & Services, Strategies & Financials 7. Healthcare Policies and Regulatory Landscape. A. Policy changes and Reimbursement scenario 8. Factors Driving Future Growth.. A. New Trends and Development of Gene Therapy for Hemophilia market B. Future Opportunities 9. Barriers in Future Growth. 10. Conclusion

The report also looks at key players competitive environment in terms of product, value, financial situation, product portfolio, growth strategy, and regional presence. The study includes a value chain analysis and a SWOT analysis to address the issue of whether shareholders should concentrate their efforts and investments in the near future on the Gene Therapy for Hemophilia markets emerging segment. Furthermore, the report is a collective presentation of primary and secondary research findings.

Buy [emailprotected]https://insights10.com/checkout/

Contact:

Email :[emailprotected]

ContactNumber :+91 79 4009 3656

Continue reading here:
Gene Therapy for Hemophilia Market will Reach Thriving Value by 2019 to 2028 SoccerNurds - SoccerNurds

→←